Rockwell Medical, Inc. logo

Rockwell Medical, Inc.

RMTI

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Latest quote

$8.01

+$0.46 · +6.02%

Aug 21, 3:55 PM ET

RMTI company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

50

Fair Value

Momentum

17

Strong Down

Sentiment

59

Mixed

Risk resilience

23

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
Mark Strobeck
Listed since
Jan 27, 1998
Employees
157

Market position

Volume
25.81K
0.77× average
Average volume
33.53K
Average daily volume
Market cap
31.97M USD
Beta
1.62
Market reference 1

Financials

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends24%-4%-32%-60%Gross margin, FY2021: -3.91%Gross margin, FY2022: 5.60%Gross margin, FY2023: 10.41%Gross margin, FY2024: 17.23%Gross margin, FY2025: 16.89%Operating margin, FY2021: -48.98%Operating margin, FY2022: -23.05%Operating margin, FY2023: -7.98%Operating margin, FY2024: 0.60%Operating margin, FY2025: -6.77%Net margin, FY2021: -52.76%Net margin, FY2022: -25.65%Net margin, FY2023: -10.09%Net margin, FY2024: -0.47%Net margin, FY2025: -7.67%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -3.91%. Gross margin FY2022 5.60%. Gross margin FY2023 10.41%. Gross margin FY2024 17.23%. Gross margin FY2025 16.89%. Operating margin FY2021 -48.98%. Operating margin FY2022 -23.05%. Operating margin FY2023 -7.98%. Operating margin FY2024 0.60%. Operating margin FY2025 -6.77%. Net margin FY2021 -52.76%. Net margin FY2022 -25.65%. Net margin FY2023 -10.09%. Net margin FY2024 -0.47%. Net margin FY2025 -7.67%.

Income trends

Revenue

69.26M USD-31.76%

Operating income

−4.69M USD−5.3M USD

Net income

−5.31M USD-1007.08%
Income trends across reported periods114.91M USD61.24M USD7.57M USD−46.09M USDRevenue, FY2021: 61.93M USDRevenue, FY2022: 72.81M USDRevenue, FY2023: 83.61M USDRevenue, FY2024: 101.49M USDRevenue, FY2025: 69.26M USDOperating income, FY2021: −30.34M USDOperating income, FY2022: −16.78M USDOperating income, FY2023: −6.67M USDOperating income, FY2024: 608K USDOperating income, FY2025: −4.69M USDNet income, FY2021: −32.67M USDNet income, FY2022: −18.68M USDNet income, FY2023: −8.44M USDNet income, FY2024: −480K USDNet income, FY2025: −5.31M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 61.93M USD. Revenue FY2022 72.81M USD. Revenue FY2023 83.61M USD. Revenue FY2024 101.49M USD. Revenue FY2025 69.26M USD. Operating income FY2021 −30.34M USD. Operating income FY2022 −16.78M USD. Operating income FY2023 −6.67M USD. Operating income FY2024 608K USD. Operating income FY2025 −4.69M USD. Net income FY2021 −32.67M USD. Net income FY2022 −18.68M USD. Net income FY2023 −8.44M USD. Net income FY2024 −480K USD. Net income FY2025 −5.31M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue69.26M USD101.49M USD83.61M USD72.81M USD61.93M USD
Cost of goods sold57.56M USD84.01M USD74.91M USD68.73M USD64.35M USD
Gross profit11.7M USD17.48M USD8.7M USD4.08M USD−2.42M USD
Research and development19K USD1.11M USD3.12M USD6.84M USD
Selling, general, and administrative16.39B USD16.86M USD14.27M USD17.74M USD21.08M USD
Operating expenses16.39M USD16.88M USD15.37M USD20.86M USD27.92M USD
Interest income234K USD92K USD211K USD33K USD22K USD
Interest expense1.12M USD1.25M USD2.3M USD1.94M USD2.36M USD
Depreciation and amortization2.19M USD2.18M USD1.44M USD576K USD2.52M USD
Operating income−4.69M USD608K USD−6.67M USD−16.78M USD−30.34M USD
Net income−5.31M USD−480K USD−8.44M USD−18.68M USD−32.67M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

16 ratings
Strong buy00%
Buy1063%
Hold213%
Sell425%
Strong sell00%

Recent analyst actions

2 institutions
HC Wainwright& Co.maintainBuy

RMTI news

RMTI peers

ETFs holding RMTI

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research RMTI

research.disclaimer